Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer (opens in a new tab)
TerminatedPhase 1/2
Carcinoma, Merkel CellPolyomavirus InfectionsXmAb18087XmAb18087 ± Pembrolizumab
Dr. Sandra P. Dangelo, MD
NPI1356509277PAC ID2062680713
- Medicare services, 2024
- 459
- Medicare patients, 2024
- 131
- Part D claims, 2024
- 229
- Clinical trials
- 7
- MIPS score, 2024
- 76
- Practice address
- 1275 York Avenue, New York, NY 10065
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Dangelo's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Sandra P. Dangelo is a medical oncologist in New York, New York
Dr. Dangelo practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.
Dr. Dangelo's NPI, 1356509277, was assigned on May 28, 2008. Dr. Dangelo graduated from SUNY Downstate Health Sciences University in 2004. Dr. Dangelo holds New York license 237662.
NPI and contact details
- NPI
- 1356509277NPI Registry (opens in a new tab)
- Medicare PAC ID
- 2062680713
- NPI enumeration date
- May 28, 2008
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Female
- Estimated age
- 48
- Medical school graduation
- 2004
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Sandra P. Dangelo practices at Memorial Sloan Kettering Cancer Center in New York, New York
Dr. Dangelo's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.
- Memorial Sloan Kettering Cancer Center1275 York Avenue, New York, NY 10065
Source: Dmand AI Affiliation Data
Dr. Sandra P. Dangelo is affiliated with 1 site of care and 3 medical groups
Dr. Dangelo's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Dangelo to 2 more medical groups, each named with a free account.
Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Sandra P. Dangelo's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dangelo practices. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Memorial Sloan Kettering Cancer Center | Available with a free account |
| +2 medical groups | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every hospital where Dr. Dangelo practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across Memorial Sloan Kettering Cancer Center and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Sandra P. Dangelo is one of 458 medical oncologists in New York
Medical oncology is Dr. Dangelo's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Dangelo is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Dangelo's licenses on file in 4 states: New York, Florida, New Jersey and Pennsylvania.
Specialties and state licenses
- Medical oncology, New YorkPrimary
- Florida license
- New Jersey license
- Pennsylvania license
Clinical focus
Dmand AI lists lung cancer, lymphoma and prostate cancer among the conditions Dr. Dangelo treats.
Medical oncologists near Dr. Dangelo
Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.
458medical oncologists in New York330medical oncologists in New York141medical oncologists at Memorial Sloan Kettering Cancer Center
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Sandra P. Dangelo billed Medicare for 459 services in 2024
CMS data shows 459 Medicare services from Dr. Dangelo across 3 procedure codes in 2024, for 131 Medicare patients. Medicare paid $36,614 for them. Every service was in an office.
Medicare services, 2024459
Medicare patients131
Paid by Medicare$36,614
Procedure codes3
Dr. Dangelo's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Office and hospital visits
- 2023: 4572024: 38815%
- Other services
- 2023: 02024: 71
Dr. Dangelo compared with the New York median for medical oncologists, 2024
- Dr. Dangelo
- New York median
- Medicare services
- 459vs 34035% above
- Medicare patients
- 131vs 11217% above
- Part D claims
- 117vs 13010% below
Medians across 421 medical oncologists in New York with Dmand AI profiles that report each measure.
Dr. Dangelo's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Dangelo?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Dangelo and other medical oncologists in New York.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Sandra P. Dangelo treated 131 Medicare patients in 2024, average age 75
CMS counts 131 Medicare patients who saw Dr. Dangelo in 2024. The largest group is 65 to 74, with 65 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 13% are also on Medicaid. Their average risk score is 3.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.
Across all payers, Dmand AI patient panel data puts Dr. Dangelo's median patient age at 70, with 49% women.
Medicare patients, 2024131
Average age75
Average risk score3.07
Also on Medicaid13%
Dr. Dangelo's Medicare patients by age, 2024
CMS leaves out age groups with fewer than 11 patients.
Dr. Dangelo's Medicare patients by sex, 2024
- Women5945%
- Men7255%
Chronic conditions among Dr. Dangelo's Medicare patients, 2024
- High cholesterol75%
- High blood pressure74%
- Arthritis47%
- Cancer40%
- Ischemic heart disease40%
- Diabetes34%
- Mood disorders33%
- Anxiety29%
Share of Medicare patients with each condition. A patient can have several.
Dr. Dangelo's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 70
Patient panel by sex, all payers
- Women49%
- Men50%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Sandra P. Dangelo wrote 229 Medicare Part D claims in 2024
In 2024, Dr. Dangelo wrote 229 Medicare Part D claims for 56 patients. 87% of them were for generic drugs. CMS names the drug for 117 of them, across 7 drugs with 11 or more claims each, at $83,797 in total drug cost. In 2023, CMS named 116 claims across 7 drugs.
Part D claims, 2024229
Drugs named by CMS7
Total drug cost$83,797
Part D patients56
Dr. Dangelo's Part D claims by kind of drug, 2024
- Generic200 claims87%
- Brand-name29 claims13%
Dr. Dangelo's most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Drug classes CMS tracks in Dr. Dangelo's Part D claims, 2024
- Opioids11%26 of 229 claims
Share of all Part D claims for each drug class CMS reports on. Classes with no claims are left out.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 1162024: 1171%
Drugs named by CMS: 7 in 2024, 7 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Sandra P. Dangelo scored 76 out of 100 in Medicare's MIPS program for 2024
CMS publishes a Merit-based Incentive Payment System (MIPS) score of 76 out of 100 for Dr. Dangelo for performance year 2024, reported as part of a group. Dr. Dangelo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dangelo as offering telehealth.
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
Dr. Dangelo's MIPS scores, performance year 2024
- 76of 100Final score
- 60.6of 100Quality
- 40of 100Improvement Activities
- 74of 100Cost
Each score is out of 100. The final score weighs the categories CMS scored for this clinician.
Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026
For MedTech and pharma teams
Find medical oncologists like Dr. Dangelo by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Sandra P. Dangelo has worked on 7 clinical trials
Dmand AI links Dr. Dangelo to 7 clinical trials, 4 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Liposarcoma, Myxoid, Carcinoma, Merkel Cell and Leiomyosarcoma. Memorial Sloan Kettering Cancer Center sponsors the most, 3. Open Payments lists research payments to Dr. Dangelo that name 1 trial.
Clinical trials with Dr. Dangelo by phase
- NonePhase 1: no trials
- 2Phase 1/2: 2 trials
- 4Phase 2: 4 trials
- NonePhase 3: no trials
- NonePhase 4: no trials
Conditions in Dr. Dangelo's trials
- Liposarcoma, Myxoid
- Carcinoma, Merkel Cell
- Leiomyosarcoma
- Pancreatic Neoplasms
- Sarcoma
Investigators on the most trials with Dr. Dangelo
- Mihaela Druta, MD2 shared trials
- David A. Liebner, MD2 shared trials
- Scott M. Schuetze, MD, PhD2 shared trials
Recent clinical trials with Dr. Dangelo
Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma (opens in a new tab)
Active, not recruitingPhase 2
LenvatinibPembrolizumab
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma (opens in a new tab)
CompletedPhase 2
LeiomyosarcomaNeoplasms, Muscle TissueNivolumabRucaparib
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma (opens in a new tab)
RecruitingPhase 1/2
SarcomaNeoplasms, Connective and Soft TissueDocetaxelGemcitabineRetifanlimab
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (opens in a new tab)
Active, not recruitingPhase 2
Liposarcoma, MyxoidSarcoma, Synovialafamitresgene autoleucel (previously ADP-A2M4)
Sources: ClinicalTrials.gov (National Library of Medicine); and Dmand AI Research Linkage
Dr. Sandra P. Dangelo received $73,949 in industry payments from 2016 to 2025
CMS Open Payments shows 54 general payments to Dr. Dangelo from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. EMD Serono, Inc. paid the most, $32,697. It also lists 12 research payments totaling $1,302 in 2019, naming 1 clinical trial.
General payments to Dr. Dangelo by program year, 2016 to 2025
General payments to Dr. Dangelo by kind, 2016 to 2025
$73.9Kin total
- Consulting fees$48,89666%
- Speaker and faculty fees$17,18823%
- Travel and lodging$5,1687%
- Honoraria$1,8753%
- Food and beverage$8211%
Companies that paid Dr. Dangelo the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Sandra P. Dangelo graduated from SUNY Downstate Health Sciences University
Dr. Dangelo graduated from SUNY Downstate Health Sciences University in 2004.
- Medical school
- Board certified in medical oncology
Source: Dmand AI Professional Profile Data
Dr. Sandra P. Dangelo accepts plans from 14 insurance carriers
Dr. Dangelo is in network with 14 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.
- Aetna
- Elevance
- Excellus BlueCross BlueShield
- United Healthcare
- Blue Cross Blue Shield of Michigan
- Blue Cross Blue Shield of Massachusetts
- HCSC
- MetroPlus Health Plan
- +6 more carriersWith a free account
Plan types Dr. Dangelo accepts, by number of carriers
- Medicare10
- PPO9
- POS6
- EPO5
- HMO4
- Medicaid2
Source: Dmand AI Insurance Network Data
Sources for Dr. Sandra P. Dangelo's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab) |
| Clinical trials and co-investigators | ClinicalTrials.gov (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| Insurance carriers and plan types | Dmand AI Insurance Network Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Sandra P. Dangelo
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Sandra P. Dangelo's NPI number?
Dr. Sandra P. Dangelo's NPI number is 1356509277. It was assigned on May 28, 2008, and it is active in the NPI Registry.
What kind of doctor is Dr. Sandra P. Dangelo?
Dr. Sandra P. Dangelo is a medical oncologist in New York, New York. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).
Where does Dr. Sandra P. Dangelo practice?
Dr. Dangelo practices at 1275 York Avenue, New York, NY 10065. Dr. Dangelo's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Dangelo to 2 medical groups.
What is Dr. Sandra P. Dangelo's medical license number?
Dr. Dangelo holds New York license 237662, one of the licenses on file in 4 states.
Which states has Dr. Sandra P. Dangelo been licensed in?
Dmand AI has state licenses on file for Dr. Dangelo in New York (2005 to 2027), Florida (since 2021), New Jersey (2019 to 2027) and Pennsylvania (2024 to 2026).
Which hospitals is Dr. Sandra P. Dangelo affiliated with?
Dr. Dangelo practices at Memorial Sloan Kettering Cancer Center in New York, New York.
What medical group is Dr. Sandra P. Dangelo part of?
Dr. Dangelo is linked to Memorial Sloan Kettering Cancer Center. Dmand AI links Dr. Dangelo to 2 more medical groups.
Does Dr. Sandra P. Dangelo accept Medicare?
Yes. CMS data shows Dr. Dangelo billed Medicare for 459 services in 2024, and Dr. Dangelo accepts Medicare assignment.
Does Dr. Sandra P. Dangelo offer telehealth?
Yes. The CMS Doctors and Clinicians file lists Dr. Dangelo as offering telehealth services.
What is Dr. Sandra P. Dangelo's MIPS score?
Dr. Dangelo's MIPS final score for performance year 2024 is 76 out of 100, reported as part of a group.
Show 9 more questionsShow fewer questions
How many Medicare patients does Dr. Sandra P. Dangelo see?
CMS counts 131 Medicare patients who saw Dr. Dangelo in 2024, with an average age of 75.
Is Dr. Sandra P. Dangelo board certified?
Yes. Dr. Dangelo is board certified in medical oncology by the American Board of Internal Medicine.
What services does Dr. Sandra P. Dangelo bill to Medicare?
In 2024, Dr. Dangelo's most billed Medicare services were office visit, established patient (99214), medicare service (G2211) and office visit, new patient (99204).
Where did Dr. Sandra P. Dangelo go to medical school?
Dr. Dangelo graduated from SUNY Downstate Health Sciences University in 2004.
What drugs does Dr. Sandra P. Dangelo prescribe most?
In 2024 Medicare Part D data, Dr. Dangelo's most prescribed drugs by claims were Imatinib Mesylate, Levothyroxine Sodium and Ondansetron HCl.
Has Dr. Sandra P. Dangelo received payments from drug or device companies?
CMS Open Payments shows $73,949 in general payments to Dr. Dangelo from 9 companies from 2016 to 2025. The largest total came from EMD Serono, Inc.
How long has Dr. Sandra P. Dangelo been practicing?
Dr. Dangelo graduated from medical school in 2004, 22 years ago.
Does Dr. Sandra P. Dangelo do research?
Dr. Dangelo has worked on 7 clinical trials.
What insurance does Dr. Sandra P. Dangelo accept?
Dr. Dangelo is in network with 14 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.
Selling to medical oncology practices?
See medical oncologists in New York by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card